Global Thrombocythemia Market – Industry Trends and Forecast to 2029

Análise e dimensão do mercado da trombocitemia

Espera-se que o mercado global de trombocitemia testemunhe um crescimento significativo durante o período de previsão. De acordo com a MPN Research Foundation, a Trombocitemia Essencial (TE) é uma neoplasia mieloproliferativa crónica (NMP) tipicamente caracterizada por uma acumulação de um grande número de plaquetas no sangue. O diagnóstico desta doença baseia-se em análises ao sangue, como o rastreio genético, hemograma completo, investigação de esfregaço de sangue e exames de medula óssea. Poucos doentes podem não apresentar sintomas, mas apresentam uma contagem crescente de plaquetas. Em alguns doentes, os sintomas não são visíveis, mas apresentam um aumento da contagem de plaquetas. O COVID-19 também teve um grande impacto no crescimento do mercado.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado global de trombocitemia no período de previsão 2022-2029. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado da trombocitemia

Definição de mercado

A trombocitemia, também conhecida como trombocitose, é uma doença hemorrágica hematológica caracterizada por uma concentração de plaquetas no sangue anormalmente elevada. As plaquetas são o principal componente do sangue responsável pela coagulação sanguínea. O aumento da contagem de plaquetas pode levar a uma coagulação excessiva ou insuficiente. Esta doença ocorre devido à mutação nos genes JAK2, CALR. Estas mutações levam à sinalização hiperativa anormal de uma via denominada via JAK. levando a trombocitemia.  

Dinâmica global do mercado da trombocitemia

Motoristas

• Prevalência de trombocitemia

De acordo com os relatórios, a população total prevalente de trombocitemia foi de 232.688 em 2017. A prevalência crescente estimada de trombocitemia nos Estados Unidos foi de cerca de 142.635 casos em 2017. A taxa de incidência de trombocitemia em mulheres é 1,5 vezes superior que nos homens . Isto impulsiona o crescimento do mercado.

• Processo crescente de desenvolvimento de medicamentos

Vários medicamentos estão a ajudar a impulsionar o crescimento do mercado. Medicamentos como a hidroxiureia, a anagrelida e o interferão alfa-2b são populares no tratamento. A plaquetasférese é utilizada muito raramente, o que significa a remoção de plaquetas . São poucos os doentes assintomáticos que não necessitam de qualquer tratamento. Um medicamento chamado IMG-7289 está em ensaio clínico de fase 2 para tratar a trombocitemia. A trombocitemia afeta cerca de 1 a 24 por 1 milhão de pessoas em todo o mundo.

Oportunidades

• Aumento da população idosa

Segundo pesquisas, a população idosa está mais propensa a sofrer desta doença. De acordo com os relatórios da Aging World de 2015, existiam aproximadamente 562 milhões de pessoas com 65 anos ou mais em todo o mundo, o que aumentou a incidência da doença e impulsionou o crescimento do mercado da trombocitotemia.

• Aumento da procura por farmácias de retalho

O aumento do número de medicamentos para a trombocitotemia entregues através das farmácias de retalho e o aumento do número de farmácias de retalho nos países desenvolvidos criam oportunidades para o crescimento do mercado. Além disso, os doentes preferem as farmácias de retalho para comprar medicamentos, pois são de fácil acesso.

 Restrições/Desafios

• Efeitos secundários dos tratamentos

There are various side-effects associated with the treatment options of idiopathic thrombocytopenic purpura. Side effects such as fluid retention, heart problems, headaches, dizziness, nausea and diarrhea hamper the market growth. Additionally, Interferon alfa-2b (Intron A) or peginterferon alfa-2a (Pegasys) given in the form of injection, and may cause severe side effects than hydroxyurea or anagrelide does. Thus, this hampers the market growth.

• Increased Cost of Screening

The high cost associated with the diagnosis, mainly genetic screening is a significant setback for its market growth. Diagnosis involves tests such as complete blood count, blood smear investigation, genetic screening and bone marrow testing, which require huge expenditure. This hampers the market growth.

This global thrombocythemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global thrombocythemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Thrombocythemia Market

COVID-19 disease mainly affects the lungs, but it could cause complex multiorgan effects. Mnay earlier studies showed that thrombosis has been complicated with COVID-19 infection. Thrombocythemia could cause thrombosis complicated with COVID-19. The healthcare professionals should consider the possibility of thromboembolic events. Thrombocytopenia has been witnessed in patients hospitalized with COVID-19, and lower platelet counts are related with worse clinical outcomes. Thus, COVID-19 left a major impact on the global thrombocythemia market.

Global Thrombocythemia Market Scope

The global thrombocythemia market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Anti-Platelet Treatment
• Platelet-Lowering
• Antineoplastic Agent
• Others

Route of Administration

• Oral
• Injectable

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Thrombocythemia Market Regional Analysis/Insights

The global thrombocythemia market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global thrombocythemia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global thrombocythemia market throughout the forecasted period due to high prevalence of bleeding disorders.

North America dominates the market due to the high demand for disease-specific treatment, the rise in adoption of newer technologies, the presence of refined healthcare infrastructure and increased patient awareness.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Thrombocythemia Market Share Analysis

The global thrombocythemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to global thrombocythemia market.

Key players operating in the global thrombocythemia market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (Japan)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Boehringer Ingelheim International Gmbh (Germany)
• Sanofi (France)
• Astrazeneca (U.K.)
• AbbVie Inc. (U.S.)

SKU-54194